Leading Off: Pharmaceuticals in the Dry Eye Disease Pipeline - Takeaways - MDSpire

Leading Off: Pharmaceuticals in the Dry Eye Disease Pipeline

New innovations targeting dry eye disease (DED) are in the pipeline to enable us to tailor our treatments to the specific underlying causes of DED.

  • By

  • SHANE R. KANNARR, OD

  • Christoper J. Jacquinot, OD

  • Ryan A. Cedeno, OD

  • July 1, 2025

  • 1 min

Share

  • 1

    Reproxalap is a reactive aldehyde species modulator in phase 3 trials, targeting inflammation in dry eye disease and allergies.

  • 2

    AZR-MD-001 is an ophthalmic ointment in phase 3 trials aimed at improving meibum quality in patients with meibomian gland dysfunction.

  • 3

    OCS-02, an anti-TNFa drop in phase 2 trials, is designed to treat ocular inflammation and apoptosis related to dry eye disease.

  • 4

    Softacort, currently in phase 4 trials, is an anti-inflammatory that may relieve symptoms of meibomian gland dysfunction.

  • 5

    New treatments for dry eye disease are being developed to address specific underlying causes, enhancing personalized patient care.

Original Source(s)

Leading Off: Pharmaceuticals in the Dry Eye Disease Pipeline

  • by SHANE R. KANNARR, OD, Christoper J. Jacquinot, OD, Ryan A. Cedeno, OD

  • July 1, 2025

Related Content

Women and Dry Eye

Presenters at Optometry's Meeting noted that hormonal status and cosmetic use can significantly affect test results and dry eye disease presentation.

Ocular Surface Control: A Modern Approach to Peri-operative Dry Eye Management

Join us for a focused webinar exploring a modern approach to peri-operative dry eye management

  • April 22, 2026

  • 1 min
Wogonoside alleviates hyperosmotic stress-induced inflammation and apoptosis in human corneal epithelial cells via PI3K/AKT signaling